Testing lasting protection from a single malaria vaccine dose
Part of Infections clinical trials.
This study checks how long the protection from an earlier malaria vaccine (called GA2) lasts after a single dose. It involves being exposed to malaria again to see if you are still protected.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 35 years old and in good health.
- You took part in the earlier CoGA study and received the first dose of the malaria vaccine, and you were protected when later exposed to malaria.
- You have no history of malaria or prior participation in other malaria studies (unless you are in the rechallenge group).
- You do not have certain conditions like sickle cell disease, thalassemia, or a weakened immune system.
- You are not taking immunosuppressive drugs or certain antibiotics in the 3 months before the study.
- If you can become pregnant, you agree to use contraception and not breastfeed during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of experimental malaria vaccines to see if they are safe and help protect against malaria. It includes both adults and young children in malaria-affected areas.
This study tests a genetically modified malaria parasite that is intentionally given to healthy volunteers through a mosquito bite. The goal is to see if it is safe and to learn how the immune system responds, which could help develop a malaria vaccine.
This trial tests a new malaria drug (MMV055), alone or with another drug (MMV371), to see if it is safe and how the body processes it. It is for healthy people who want to help find new malaria treatments.
This study tests a new malaria vaccine in healthy adults. You will receive the vaccine and then be exposed to the malaria parasite in a controlled setting to check if the vaccine protects you.
This study tests a new long-acting injection to prevent malaria. It checks safety and how the body handles the drug in healthy adults and adolescents in Rwanda.
This study tests a new investigational drug (GSK4425689A) for the first time in humans. It is a healthy volunteer study to check the safety, side effects, and how the drug moves through the body. It may help in the future development of treatments for malaria.
Hear when a new Malaria Falciparum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.